Role of TSC-mTOR pathway in diabetic nephropathy

被引：54

作者：

Inoki, Ken ^{[1
,2
]}

机构：

[1] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48108 USA

[2] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2008年 / 82卷

关键词：

Diabetes; mTOR; TSC; Rapamycin; Diabetic nephropathy;

D O I：

10.1016/j.diabres.2008.09.028

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

TsC-mTOR signaling plays a crucial role in the regulation of cell growth and survival control. Mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine kinase that forms two distinct functional complexes, termed TOR complex 1 (TORC1) and TORC2, respectively. TORC1 is a rapamycin-sensitive complex and regulates a wide array of cellular processes including translation, transcription, and autophagy. Tuberous sclerosis complex (TSC) gene products, TSC1 and TSC2 are tumor suppressors and specifically suppress TORC1 activity. Mutation of either TSC1 or TSC2 causes TSC disease, which is characterized by formation of hamartomas in multiple organs. Although the role of TSC-mTOR pathway in tumor and cancer development has been extensively studied, more recent studies have indicated a role for mTOR function in appetite, memory, aging, and energy metabolism. Dysregulation of the TSC-mTOR pathway may cause not only tumor development but also metabolic disorders such as diabetes and its complications. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：S59 / S62

页数：4

共 29 条

[1]

The lack of cyclin kinase inhibitor p27Kip1 ameliorates progression of diabetic nephropathy [J].

Awazu, M ;

Omori, S ;

Ishikura, K ;

Hida, M ;

Fujita, H .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (03) :699-708

[2]

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis [J].

Bissler, John J. ;

McCormack, Francis X. ;

Young, Lisa R. ;

Elwing, Jean M. ;

Chuck, Gail ;

Leonard, Jennifer M. ;

Schmithorst, Vincent J. ;

Laor, Tal ;

Brody, Alan S. ;

Bean, Judy ;

Salisbury, Shelia ;

Franz, David N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (02) :140-151

[3]

TSC2 regulates VEGF through mTOR-dependent and -independent pathways [J].

Brugarolas, JB ;

Vazquez, F ;

Reddy, A ;

Sellers, WR ;

Kaelin, WG .

CANCER CELL, 2003, 4 (02) :147-158

[4]

Pathogenesis, prevention, and treatment of diabetic nephropathy [J].

Cooper, ME .

LANCET, 1998, 352 (9123) :213-219

[5]

Raptor-rictor axis in TGFβ-induced protein synthesis [J].

Das, Falguni ;

Ghosh-Choudhury, Nandini ;

Mahimainathan, Lenin ;

Venkatesan, Balachandar ;

Feliers, Denis ;

Riley, Daniel J. ;

Kasinath, Balakuntalam S. ;

Choudhury, Goutam Ghosh .

CELLULAR SIGNALLING, 2008, 20 (02) :409-423

[6]

De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993

[7]

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα but not S6K1 [J].

Guertin, David A. ;

Stevens, Deanna M. ;

Thoreen, Carson C. ;

Burds, Aurora A. ;

Kalaany, Nada Y. ;

Moffat, Jason ;

Brown, Michael ;

Fitzgerald, Kevin J. ;

Sabatini, David M. .

DEVELOPMENTAL CELL, 2006, 11 (06) :859-871

[8]

ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells [J].

Hafizi, S ;

Wang, XM ;

Chester, AH ;

Yacoub, MH ;

Proud, CG .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 287 (03) :H1232-H1238

[9]

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins [J].

Harrington, LS ;

Findlay, GM ;

Gray, A ;

Tolkacheva, T ;

Wigfield, S ;

Rebholz, H ;

Barnett, J ;

Leslie, NR ;

Cheng, S ;

Shepherd, PR ;

Gout, I ;

Downes, CP ;

Lamb, RE .

JOURNAL OF CELL BIOLOGY, 2004, 166 (02) :213-223

[10]

Dysregulation of the TSC-mTOR pathway in human disease [J].

Inoki, K ;

Corradetti, MN ;

Guan, KL .

NATURE GENETICS, 2005, 37 (01) :19-24

← 1 2 3 →